Outlook Therapeutics, Inc. (OTLK): Price and Financial Metrics
GET POWR RATINGS... FREE!
OTLK Stock Price Chart Interactive Chart >
OTLK Price/Volume Stats
|Current price||$1.09||52-week high||$3.27|
|Prev. close||$1.03||52-week low||$0.68|
|Day high||$1.12||Avg. volume||1,332,720|
|50-day MA||$1.40||Dividend yield||N/A|
|200-day MA||$1.67||Market Cap||246.28M|
Outlook Therapeutics, Inc. (OTLK) Company Bio
Outlook Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. The Company engages in identifying, developing, manufacturing, and commercializing complex biosimilar therapeutics. Outlook Therapeutics focuses on monoclonal antibodies in the disease areas of immunology and oncology aspects. Outlook Therapeutics offers its services in the United States.
Most Popular Stories View All
OTLK Latest News Stream
|Loading, please wait...|
OTLK Latest Social Stream
View Full OTLK Social Stream
Latest OTLK News From Around the Web
Below are the latest news stories about Outlook Therapeutics Inc that investors may wish to consider to help them evaluate OTLK as an investment opportunity.
Pivotal Phase 3 data from the NORSE TWO registration trial to be presented by Lawrence Lee, MD, MBBS, FRANZCO, FRACSISELIN, N.J., Feb. 24, 2022 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, today announced that Lawrence Lee, MD, MBBS, FRANZCO, FRACS, Associate Professor of Ophthalmology at the University of Queensland and Director
With the business potentially at an important milestone, we thought we'd take a closer look at Outlook Therapeutics...
There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Veru (VERU – Research Report), Outlook Therapeutics (OTLK – Research Report) and Inventiva (IVA – Research Report) with bullish sentiments. Veru (VERU) In a report released today, Yi Chen from H.C. Wainwright reiterated a Buy rating on Veru, with a price target of $21.00. The company's shares closed last Monday at $6.07, close to its 52-week low of $4.37. According to TipRanks.
Outlook Therapeutics Reports Financial Results for First Quarter Fiscal Year 2022 and Provides Corporate Update
Outlook Therapeutics remains on track to submit new U.S. FDA Biologics License Application (BLA) for first ophthalmic formulation of bevacizumab Commercial launch planning underway Financed through the anticipated approval of the ONS-5010 BLA ISELIN, N.J., Feb. 14, 2022 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, today announced
Live video webcast presentation on Friday, February 18th at 10:40 AM ET Live video webcast presentation on Friday, February 18th at 10:40 AM ET
OTLK Price Returns
Continue Researching OTLKHere are a few links from around the web to help you further your research on Outlook Therapeutics Inc's stock as an investment opportunity:
Outlook Therapeutics Inc (OTLK) Stock Price | Nasdaq
Outlook Therapeutics Inc (OTLK) Stock Quote, History and News - Yahoo Finance
Outlook Therapeutics Inc (OTLK) Stock Price and Basic Information | MarketWatch